Rana R. McKay, MD
The treatment landscape for of metastatic renal cell carcinoma (RCC) has rapidly evolved of over the last decade to include more targeted options, and specifically novel immunotherapy regimens, according to Rana R. McKay, MD.
, McKay, a medical oncologist and assistant professor at the Moores Cancer Center at the University of California, San Diego, discussed the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.
OncLive: How is the management of advanced RCC evolving?
: The treatment landscape for metastatic RCC has been rapidly evolving over the past 12 years. There have been multiple new agents approved, starting in the VEGF tyrosine kinase inhibitor area, as well as some immunotherapies. The field has been rapidly evolving into looking at combinations of immunotherapy with VEGF- targeted therapy, immunotherapy combinations, and new targets.
Could you touch on one 1 or two 2 milestones of the past year?
One of the landmark studies of the past couple of years was CheckMate-025. This was a phase III study looking at second-line treatment for patients with metastatic clear- cell RCC. Patients were randomized to receive treatment with nivolumab and everolimus (Afinitor). It was the first time that a treatment in the second-line setting was shown to improve overall survival (OS) for patients with metastatic clear- cell RCC.
... to read the full story